Global Home Global Home
UNITED STATES

 

A New Era in Anti-Infectives

 

NEWS

Oculus websites contain information about products, which may or may not be available in any particular country, and if applicable, may have received approval or market clearance by a governmental regulatory body for different indications and restrictions in different countries. Each country has specific laws, regulations and medical practices governing the communication of medical or other information about medical products on the Internet. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product, which is not authorized by the laws and regulations of the country where the reader resides.

This site may contain information on medical and health-related topics. This information is not meant to be a substitute for the advice provided by your own physician or other medical professional. You should not use this information for diagnosing a health problem or disease but should always consult your own physician.

These press releases about Oculus Incorporated are sorted by date, with the most recent at the top. You will need the free Adobe® Reader® to view the PDFs.

Current Press Releases
........................................................................................................................................................................

May 1st, 2013
Oculus Innovative Sciences Announces New Regulatory Approvals for Microcyn(R)-Based Antiseptic Products in Panama and El Salvador

April 24th, 2013
Oculus Innovative Sciences Announces New Regulatory Approvals and Target Launch Dates for Three New Microcyn(R)-Based Products in Middle East Countries

April 10th, 2013
Oculus Innovative Sciences to Rollout Five New Microcyn(R) Technology-Based Products in Singapore and Malaysia

April 4th, 2013
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of Three New International Patents for Microcyn(R) Technology

March 28th, 2013
Oculus Innovative Sciences Announces Reverse Split of Common Stock

March 26th, 2013
Oculus Innovative Sciences Expands Regulatory Claims for Microcyn-Based Advanced Wound Management Products in Europe

March 20th, 2013
Oculus Innovative Sciences Appoints Jerry McLaughlin to Its Board of Directors

March 14th, 2013
Oculus Innovative Sciences Announces Completion of Patient Follow-Up in Scar Management Study

March 12th, 2013
Oculus Innovative Sciences Announces Closing of Public Offering of 8,625,000 Shares of Common Stock

March 7th, 2013
Oculus Innovative Sciences, Inc. Announces Full Exercise of Underwriters' Over-Allotment Option